U.S. Residential REITs Stock News

Star Bulk Carriers (SBLK) reported second quarter 2026 earnings on August 5, alongside a new quarterly cash dividend. The announcement provides fresh data on profitability and shareholder payouts to help you assess the stock. See our latest analysis for Star Bulk Carriers. Despite the recent earnings beat and higher dividend, Star Bulk Carriers’ share price has eased 1.66% over the last day and 1.08% over the past week. However, its year to date share price return of 46.72% and 1 year total...

Celsius Holdings stock has seen a steep reset over the past few years, yet the valuation checks still lean toward the shares looking expensive rather than obviously cheap. After a sharp decline in the share price, investors are weighing up whether the current level properly reflects the business risks and opportunities now on the table. Celsius Holdings has fallen about 55% over the past 3 years, which puts recent trading firmly in a recovery phase rather than a momentum phase for existing...

TransDigm Group Incorporated recently reported its third-quarter and nine‑month results for the period ended June 27, 2026, with sales rising to US$2,741 million and net income to US$539 million for the quarter, and nine‑month sales reaching US$7,569 million with net income of US$1,519 million. Alongside these results, the company raised its full‑year 2026 outlook for net sales, net income and earnings per share, signaling management’s increased confidence relative to its earlier...

Recent share performance context Wyndham Hotels & Resorts (WH) has drawn fresh attention after a period of weaker share performance, with the stock down 3.3% over the past day and 9.2% over the past month. For investors tracking longer trends, the stock has declined 12.8% over the past 3 months and 13.2% over the past year, against a backdrop of annual revenue of US$1.42b and net income of US$207 million. See our latest analysis for Wyndham Hotels & Resorts. At a share price of US$71.35,...

In recent days, Ondas Holdings completed its acquisition of Cyberhawk, expanded its defense footprint with a multi‑million‑dollar Israeli Ministry of Defense tender for next‑generation tactical attack drones, and saw Sentrycs’ counter‑drone system deployed for NFL game security at EverBank Stadium, alongside filing a US$226.76 million shelf registration for ESOP‑related common stock. Together, these moves highlight Ondas’ push to build an integrated unmanned systems and...

In early August 2026, Synopsys highlighted new AI-driven chip design tools, including certified support for Intel’s 14A process and autonomous design workflows developed with Microsoft and evaluated by AMD, alongside reporting strong fiscal 2026 revenue growth and a higher full-year outlook. This combination of advanced AI design automation, deeper foundry alignment, and accelerating demand from chipmakers underscores Synopsys’ expanding role at the center of next-generation semiconductor...

Kratos Defense & Security Solutions has delivered a very large 3-year return while its current checks still flag the stock as expensive rather than a clear bargain. Recent contract wins and program updates have kept attention on the growth story, but the valuation profile has not yet shifted into value territory. Over the past 3 years the stock has returned about 2.9x, which puts extra focus on whether the current price already reflects much of the good news. Expectations around hypersonics...

Spotify guidance and recent earnings put fresh focus on SPOT stock Spotify Technology (NYSE:SPOT) has investors’ attention after issuing third quarter 2026 guidance alongside second quarter results, including expected revenue of about €5.0b, forecast operating income of €670m, and a projected gross margin of 32.9%. See our latest analysis for Spotify Technology. Spotify Technology’s latest guidance and second quarter results come after a period where momentum has picked up in the near term,...

With the Federal Reserve holding rates at 3.5% to 3.75% and talking about “higher for longer,” income investors are rethinking where dividends might fit in their portfolios. Elevated borrowing costs can pressure some companies and reinforce others, which creates a real opportunity for investors who pay attention. This article walks through three dividend stocks from the screener that appear positively exposed to this rate driven backdrop. The three dividend stocks discussed next are just a...

Hims & Hers Health (HIMS) is back in focus after its second quarter 2026 earnings, which showed US$753.2 million in sales alongside a shift from profit to a US$86.3 million net loss. See our latest analysis for Hims & Hers Health. Over the past year, Hims & Hers Health has combined a 26.9% 90 day share price return with a 1 year total shareholder return that declined 36.4%, which suggests recent momentum has improved even as longer term holders still sit on sizeable gains from earlier...

Why Madrigal Pharmaceuticals Earnings Are Back in Focus Madrigal Pharmaceuticals (MDGL) recently reported second quarter and six month results that showed higher net losses year over year, prompting fresh attention on the stock’s financial trajectory ahead of its upcoming investor conference. See our latest analysis for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals shares trade at $515.34, with a 7 day share price return of 6.92% and a year to date decline of 13.22%. The 1 year total...

Over the last 7 days, the United States market has risen by 2.2%, contributing to a remarkable 21% increase over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying undervalued stocks can offer potential opportunities for investors looking to capitalize on companies that may be trading below their intrinsic value despite strong market performance.

The United States market has shown robust performance, climbing 2.2% in the last week and rising 21% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often reflect strong internal confidence and potential for sustained success.

The market has climbed 2.2% in the last 7 days and is up 21% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer surprising value when built on solid financials. In this article, we explore three penny stocks that combine balance sheet strength with potential for outsized gains, offering investors a chance to discover hidden value in quality companies.

The United States market has experienced a notable uptick, rising 2.2% over the last week and 21% over the past year, with earnings projected to grow by 17% annually. In such a promising environment, identifying dividend stocks that offer both steady income and potential for capital appreciation can be an effective strategy for investors looking to bolster their portfolios.

Parents now have fresh tax rules to work with, and that could quietly reshape where household savings flow next. With Trump Accounts opening the door to pre tax contributions for children, more money may sit in investments for longer. That is why investors are watching which financial services and asset management stocks are closely tied to this trend. This article walks through three such stocks from the screener and how they might be affected. The three stocks below are just a sample, with...

Zai Lab (ZLAB) is back in focus after its second quarter 2026 earnings update, which showed revenue of US$106.31 million and a wider net loss, alongside fresh attention on newly approved products in China. See our latest analysis for Zai Lab. At a share price of US$23.57, Zai Lab has seen strong short term momentum, with a 7 day share price return of 29.65% and year to date share price return of 36.01%. The 1 year total shareholder return is still down 32%, which signals that recent...

In recent weeks, Magnolia Oil & Gas completed a US$81.4 million share repurchase tranche, issued US$500.0 million of 6.625% senior notes due 2034 to help fund its pending WildFire acquisition, reported higher second‑quarter revenue and earnings alongside increased production, and raised its quarterly dividend to US$0.18 per share. Together, these actions highlight management’s emphasis on balance sheet-funded growth, ongoing capital returns, and an operating profile that has supported higher...

In July 2026, Axogen, Inc. reported second-quarter sales of US$69.73 million and a quarterly net loss of US$1.52 million, alongside higher year-to-date losses despite stronger revenue versus the prior year. At the same time, the company raised its full-year 2026 revenue outlook to at least US$279 million, highlighting management’s increased confidence in demand for its nerve repair portfolio despite current losses. With Axogen lifting its full-year revenue guidance, we’ll now examine how...

Q1 earnings and product update set the tone for MakeMyTrip MakeMyTrip (MMYT) is back in focus after Q1 FY 2027 results, the launch of its AI travel assistant Myra 2.0, and a confidential IPO filing for subsidiary MakeMyTrip India Limited. See our latest analysis for MakeMyTrip. At a share price of US$60.91, MakeMyTrip has seen a 35.45% 90 day share price return while its 1 year total shareholder return declined 35.57%, even though the 5 year total shareholder return is 130.20%. If Q1 results...

Life Time Group Holdings, Inc. recently reported past second-quarter 2026 results with higher sales of US$837.4 million, revenue of US$866.0 million, and net income of US$101.36 million, while also completing a US$73.37 million share repurchase under its February 2026 authorization. Alongside raising full-year 2026 revenue and net income guidance and outlining plans to open 14 mostly large-format new clubs, the company signaled a push to scale its premium fitness footprint with nearly double...

Why Royal Gold’s latest earnings and guidance matter for investors Royal Gold (RGLD) has drawn fresh attention after reporting second quarter 2026 results and issuing detailed sales guidance for the full year. The combination gives you more current information to assess the stock. For the second quarter ended June 30, 2026, the company reported sales of US$447.1 million compared with US$207.44 million a year earlier. Net income was US$236.39 million compared with US$132.35 million in the...

Why Oscar Health Stock Is Back in Focus After Guidance Shift Oscar Health (OSCR) is back on many investors’ watchlists after Q2 2026 earnings beat market expectations and the company raised its full year 2026 revenue and earnings guidance. See our latest analysis for Oscar Health. The raised guidance and stronger Q2 earnings have come after a sharp run in Oscar Health’s share price, with a year to date share price return of 84.84% and a three year total shareholder return of 298.70%. This is...

BioCryst Pharmaceuticals (BCRX) is back in focus after its second quarter 2026 report, which combined higher revenue, a sharp improvement in quarterly net income and a raised full year revenue outlook. See our latest analysis for BioCryst Pharmaceuticals. That earnings update landed alongside a sharp shift in sentiment around BioCryst Pharmaceuticals, with the stock posting a 4.90% 1 day share price return and an 11.69% 7 day share price return. The 1 year total shareholder return of 20.00%...